An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus.

Autor:	Jacobson IM; NYU Langone Health and NYU Grossman School of Medicine., Brown RS Jr; Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY., McMahon BJ; University of Washington, Seattle, WA.; University of Alaska.; Alaska Native Tribal Health Consortium, Anchorage, AK., Perrillo RP; Hepatology Division, Baylor Scott and White Medical Center, University of Texas Southwestern, Dallas, TX., Gish R; Loma Linda University, Loma Linda.; UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA.; University of Nevada Las Vegas and Reno Schools of Medicine, Las Vegas, NV.
Jazyk:	angličtina
Zdroj:	Journal of clinical gastroenterology [J Clin Gastroenterol] 2022 Jul 01; Vol. 56 (6), pp. 478-492. Date of Electronic Publication: 2022 Apr 07.
DOI:	10.1097/MCG.0000000000001695
Abstrakt:	The hepatitis B virus (HBV) is highly infectious, with over 292 million chronically infected people worldwide and up to 2.4 million in the United States. Following infection, clinically silent liver damage can ensue, but symptoms or signs of advanced disease, including cirrhosis and hepatocellular carcinoma, can take decades to emerge. HBV has the heaviest public health burden of all hepatitis viruses and has now surpassed other major communicable diseases (eg, HIV, diarrheal disease, malaria, tuberculosis) as a leading cause of death globally. Preventing transmission is essential, and efforts are in place to reinforce screening, vaccination, and routine follow-up. Three safe and effective vaccines are available in the United States and other countries for HBV prevention, and the benefits of vaccination in preventing infection and its sequelae have been substantiated. For the first time in over 25 years, a new Food and Drug Administration-approved vaccine is available that offers a high degree of immunogenicity after 2, rather than 3, injections. Persistent challenges include the underutilization of vaccination, choice of vaccine, incomplete vaccinations, varying needs in different populations, management of nonresponders or those with undocumented or incompletely documented vaccination courses, and questions about whether and when booster injections may be needed. A panel of US academic hepatologists with expertise and experience in preventing and managing HBV infection have collaborated to write this practical clinical paper intended to guide clinicians in vaccinating for HBV and address questions that regularly arise in the clinic. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu